{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-21-001284","form_type":"8-K","ticker":"ATR","cik":"0000896622","company_name":"APTARGROUP, INC.","filed_at":"2021-10-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:16.125372+00:00","generated_at":"2026-06-28T17:09:30.519967+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AptarGroup Q3 revenue $825M (+9% YoY); adjusted EPS $0.94 vs $1.01; guides Q4 $0.88-$0.96","bullets":["Reported sales $825M, +9% YoY; core sales +8%; Pharma core -2%, Beauty+Home +10%, Food+Beverage +28%.","Reported EPS $0.70 (includes $0.12 restructuring, $0.10 unrealized loss on PureCycle investment, $0.02 acquisition costs); adjusted EPS $0.94.","Adjusted EBITDA $154M; net income $47M.","Completed acquisitions: 80% of Weihai Hengyu Medical Products and majority stake in Voluntis.","Q4 2021 adjusted EPS guidance $0.88-$0.96; quarterly dividend $0.38/share payable Nov 17, 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-21-001284","json":"https://secwatch.observer/filing/0001157523-21-001284.json","markdown":"https://secwatch.observer/filing/0001157523-21-001284.md","text":"https://secwatch.observer/filing/0001157523-21-001284.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/896622/000115752321001284/0001157523-21-001284-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/896622/000115752321001284/a52517971.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T17:09:30.519967+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}